Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Metagenomi Therapeutics Inc. is managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, meaning the number of examiners is equal to the number of pending actions. The workload is spread across 2 distinct art units, which is a lower count than the 3 distinct examiners.
The busiest examiner for the portfolio is GOMEZ RODRIGUEZ, JULIO WASHINGTON: he holds 1 busiest examiner pending action. This 1 busiest examiner pending action is one of the 3 pending office actions in the total portfolio. Since the 3 pending office actions are divided among 3 distinct examiners, no single examiner handles more than one matter. The 2 distinct art units suggest that the 3 pending office actions cover at least two different technical sub-sectors within the Biotechnology & Pharmaceuticals area. Practitioners should note that the 3 distinct examiners will provide independent reviews for each of the 3 pending office actions. This distribution across 2 distinct art units requires a strategy that accounts for different technical classifications while managing the 3 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1 | 41.4% | +58.4% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
| REGLAS, GEORGIANA C | 1 | 37.7% | +36.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18056629 | ENGINEERED AND CHIMERIC NUCLEASES | REGLAS, GEORGIANA C | 26d |
| 18597260 | CLASS II, TYPE V CRISPR SYSTEMS | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18056629 | ENGINEERED AND CHIMERIC NUCLEASES | REGLAS, GEORGIANA C | 26d |
| 18597260 | CLASS II, TYPE V CRISPR SYSTEMS | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| 18488520 | ENZYMES WITH RUVC DOMAINS | ZARA, JANE J | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18597260 | CLASS II, TYPE V CRISPR SYSTEMS | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — | §101§112DP | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18488520 | ENZYMES WITH RUVC DOMAINS | ZARA, JANE J | 1637 | §112 | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18056629 | ENGINEERED AND CHIMERIC NUCLEASES | REGLAS, GEORGIANA C | 1651 | §103§112Other | Non-Final OA | 26d | Pending | Nov 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial